Emcure Pharmaceuticals Reports Strong Q2 FY27 With Revenue Up 24.3% YoY
Emcure Pharmaceuticals Ltd 路 Outcome 路 03 Nov 2026, 7:14 pm
Emcure Pharmaceuticals Reports Strong Q2 FY27 With Revenue Up 24.3% YoY Emcure Pharmaceuticals reported strong consolidated Q2 FY27 results, with revenue from operations growing 24.3% YoY (9.3% QoQ) to INR 28,205 Mn, driven by a 34.5% YoY rise in international business to INR 16,652 Mn and 12.0% YoY growth in domestic sales to INR 11,553 Mn. EBITDA increased 30.9% YoY to INR 5,748 Mn, expanding EBITDA margin by 103 bps YoY to 20.4%. Profit after tax climbed 29.3% YoY to INR 3,251 Mn with an 11.5% margin. As of 30th Sep'26, net debt stood at INR 13,171 Mn.
Original exchange filing (PDF)
More announcements from Emcure Pharmaceuticals Ltd
- Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026 路 15 Nov 2026
- Transcript of Earnings Call - Q2 FY27 held on Tuesday, November 03, 2026 at 4:00 p.m. (IST) 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026 路 06 Nov 2026
- Audio recording of Earnings Call - Q2 FY27 路 04 Nov 2026
- Presentation on Unaudited Financial Results for the quarter ended September 30, 2026 路 03 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026 路 03 Nov 2026
- For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026. 路 03 Nov 2026
